loading page

Recent Knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections
  • +4
  • My Abderrahim El Mhammedi,
  • S Saqrane,
  • S Lahrich,
  • F laghrib,
  • Y El Bouabi,
  • A farahi,
  • M Bakasse
My Abderrahim El Mhammedi
Université Sultan Moulay Slimane de Beni-Mellal
Author Profile
S Saqrane
University Sultan Moulay Slimane of Beni-Mellal
Author Profile
S Lahrich
University Sultan Moulay Slimane of Beni-Mellal
Author Profile
F laghrib
University Sultan Moulay Slimane of Beni-Mellal
Author Profile
Y El Bouabi
University Sultan Moulay Slimane of Beni-Mellal
Author Profile
A farahi
University Sultan Moulay Slimane of Beni-Mellal
Author Profile
M Bakasse
University Sultan Moulay Slimane of Beni-Mellal
Author Profile

Abstract

The management of SARS-CoV 2 has not yet been clearly determined and is based on the potential therapeutics evaluated during the SARS-CoV and MERS-CoV epidemics. Although there is currently no antiviral treatment for the treatment of human coronavirus infections, the preclinical results with remdesivir (RDV) are promising. This antiviral is identified as a drug option to be evaluated against COVID-19, based on data on its activity in vitro and in vivo on the coronaviruses MERS-CoV and SARS-CoV. Today it is used to fight coronavirus. It acts on COVID-19 by interfering with key stages in the replication cycle of the virus.